At a time when the markets appear nervous, it would be advisable to look to companies that reported attractive growth during the first quarter of the current financial year in the hope the trend extends itself.
This column reviews stocks that caught my attention, warranting a closer scrutiny when they announce their second quarter results.
Camson Biotech: For long, those who bought into the stock lived on hope. It appears their patience might start paying off. Revenues have transformed: From Rs 2.05 crore in the first quarter of 2016-17 to Rs 11.27 crore in the first quarter ...
TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
LOGIN
Not a member yet ? Resister Now
Connect using any below
WHAT YOU GET
On Business Standard Digital
On
Digital
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
Already registered ?